We recently reported that the BAD (Bcl-Xl/Bcl-2-associated death promoter homologue), as a pro-apoptotic Bcl-2 protein, shows decreased expression level, and plays an important role for predicting therapeutic response and survival in NSCLC [3]. The gene discussed is BCL2; the disease is non-small cell lung carcinoma.